

Glucoamylase from *Aspergillus niger*

An application to amend the Australia New Zealand Food Standards Code with a glucoamylase preparation produced by a genetically modified strain of *Aspergillus niger*

Table of Contents

Glucoamylase from <i>Aspergillus niger</i>	1
An application to amend the Australia New Zealand Food Standards Code with a glucoamylase preparation produced by a genetically modified strain of <i>Aspergillus niger</i> ...	1
Executive summary	4
Introduction.....	7
Chapter 3.1, General requirements for applications.....	8
A Executive summary	8
B Applicant details	8
C Purpose of the application.....	8
D Justification for the application	9
The need for the proposed change	9
The advantages of the proposed change over the status quo	9
D.1 Regulatory impact information.....	9
E Information to support the application	10
E.1 Data requirements	10
F Assessment procedure.....	10
G Confidential commercial information (CCI)	10
H Other confidential information	10
I Exclusive capturable commercial benefit (ECCB)	10
J International and other national standards.....	11
J.1 International Standards	11
J.2 Other national standards or regulations	11
K Statutory declaration	11
L Checklist.....	11
Chapter 3.3, Guidelines for applications for substances added to food	12
3.3.2 Processing Aids	12
A Technical information on the processing aid	12
A.1 Information on the type of processing aid.....	12
A.2 Information on the identity of the processing aid	12
A.3 Information on the chemical and physical properties of the processing aid	14
A.4 Manufacturing process	14
A.5 Specification for identity and purity	18
A.6 Analytical method for detection.....	19
B Information related to the safety of a chemical processing aid	19
C Information related to the safety of an enzyme processing aid	19

C.1 General information on the use of the enzyme as a food processing aid in other countries.....	19
C.2 Information on the potential toxicity of the enzyme processing aid	20
C.3 Information on the potential allergenicity of the enzyme processing aid	21
C.4 Safety assessment reports prepared by international agencies or other national government agencies, if available.....	22
D Additional information related to the safety of an enzyme processing aid derived from a microorganism	22
D.1 Information on the source microorganism	22
D.2 Information on the pathogenicity and toxicity of the source microorganism	22
D.3 Information on the genetic stability of the source organism	23
E Additional information related to the safety of an enzyme processing aid derived from a genetically-modified microorganism	23
E.1 Information on the methods used in the genetic modification of the source organism	23
F Information related to the dietary exposure to the processing aid	25
F.1 A list of foods or food groups likely to contain the processing aid or its metabolites	25
F.2 The levels of residues of the processing aid or its metabolites for each food or food group	25
F.3 For foods or food groups not currently listed in the most recent Australian or New Zealand National Nutrition Surveys (NNSs), information on the likely level of consumption	27
F.4 The percentage of the food group in which the processing aid is likely to be found or the percentage of the market likely to use the processing aid	28
F.5 Information relating to the levels of residues in foods in other countries	28
F.6 For foods where consumption has changed in recent years, information on likely current food consumption.....	28
List of references.....	29
List of appendices	31

Executive summary

The present application seeks to amend Schedule 18—Processing aids of the Australia New Zealand Food Standards Code (the Code) to approve a glucoamylase enzyme preparation produced by Novozymes.

Proposed change to Australia New Zealand Food Standards Code – Schedule 18—Processing aids

Schedule 18—Processing aids is proposed to be amended to include a genetically modified strain of *Aspergillus niger* expressing a glucoamylase from *Gloeophyllum sepiarium* as permitted source for glucoamylase.

The application is applied for assessment by the general procedure.

Description of enzyme preparation

The enzyme is a glucan 1,4- α -glucosidase (EC 3.2.1.3), commonly known as glucoamylase.

Glucoamylase catalyses the hydrolysis of (1→4)- α - as well as (1→6)- α -linkages in the starch polysaccharides amylose and amylopectin.

The enzyme is produced by submerged fermentation of an *Aspergillus niger* microorganism expressing a glucoamylase from *Gloeophyllum sepiarium*.

The glucoamylase enzyme preparation is available as a liquid preparation complying with the JECFA recommended purity specifications for food-grade enzymes.

The producing microorganism, *Aspergillus niger*, is absent from the commercial enzyme product.

Use of the enzyme

The glucoamylase enzyme preparation is used as a processing aid in brewing processes, distilled alcohol processes, and starch processing for glucose syrups production and other starch hydrolysates, and baking processes. Generally, glucoamylase degrades starch into D-glucose.

- during brewing processes the glucoamylase degrades starch into fermentable sugars.
- during beverage alcohol (distilling) processes the glucoamylase is used in order to degrade gelatinised starch and dextrins into glucose and other fermentable sugars.
- during starch processing to produce syrups the glucoamylase degrades polysaccharides into glucose.
- during baking and other cereal-based processes the glucoamylase degrades starch and dextrins into glucose that can be fermented by yeast.

Benefits

The benefits of the action of the glucoamylase in brewing processes are:

- More uniform and predictable production process and brewing yield including the possibility to control the desired level of fermentable sugars at every production

The benefits of the action of the glucoamylase in distilled alcohol production are:

- Efficient degradation of dextrans and production of fermentable sugar
- High alcohol yields due to a more complete conversion of starch and thereby less use of raw materials
- Reduced risk of infection due to high operating temperature (65°C)
- Reduced risk of infection due to low operating pH

The benefits of the action of the glucoamylase in starch processing for glucose syrups production and other starch hydrolysates are:

- Efficient degradation of dextrans and production of glucose
- Reduced risk of contamination because the enzyme can be used at high operating temperature
- Stable process allowing for variations in temperature

The benefits of the action of the glucoamylase in baking and other cereal-based processes are:

- Reduced baking time and yeast boosting
- Uniform and slightly increased volume and enhanced crust colour of the bakery product
- More uniform and predictable production of glucose
- Improved fermentability
- Uniform colour

Safety evaluation

The safety of the production organism and the enzyme product has been thoroughly assessed:

- The production organism has a long history of safe use as production strain for food-grade enzyme preparations and is known not to produce any toxic metabolites.
- The genetic modifications in the production organism are well-characterised and safe and the recombinant DNA is stably integrated into the production organism and unlikely to pose a safety concern.
- The enzyme preparation complies with international specifications ensuring absence of contamination by toxic substances or noxious microorganisms
- Sequence homology assessment to known allergens and toxins shows that oral intake of the glucoamylase does not pose food allergenic or toxic concern.
- Two mutagenicity studies *in vitro* showed no evidence of genotoxic potential of the enzyme preparation.
- An oral gavage administration study in rats for 13-weeks showed that all dose levels were generally well tolerated and no evidence of toxicity.

Furthermore, the safety of the glucoamylase preparation was confirmed by external expert groups, as follows:

- Denmark: The enzyme preparation was safety assessed resulting in the authorisation of the enzyme product by the Danish Veterinary and Food Administration.

Conclusion

Based on the Novozymes safety evaluation, confirmed by the above-mentioned body, we respectfully request the inclusion of the glucoamylase in Schedule 18—Processing aids.

Introduction

The present application describes a glucoamylase enzyme preparation produced by submerged fermentation of an *Aspergillus niger* microorganism producing a glucoamylase from *Gloeophyllum sepiarium*.

The enzyme is a glucan 1,4- α -glucosidase (EC 3.2.1.3), commonly known as glucoamylase. The enzyme catalyses the hydrolysis of (1 \rightarrow 4)- α - as well as (1 \rightarrow 6)- α -linkages in the starch polysaccharides amylose and amylopectin.

The glucoamylase enzyme preparation is intended to be used as a processing aid in the starch-processing industry to hydrolyse starch for the production of several products, e.g. beer, alcohol, syrups, bread and other cereal based products.

The following sections describe in detail the construction of the genetically modified *Aspergillus niger* used as the production organism, the production process, the product specification, the application of the enzyme preparation and finally the safety evaluation of the product including the toxicology program, which has been carried out confirming the safety of the product for its intended use.

The documentation has been elaborated according to the Application Handbook from Food Standards Australia New Zealand as of 1 July 2019, applied as relevant for an enzyme application, *i.e.* outlining the following section:

- Section 3.1.1 – General requirements
- Section 3.3.2 – Processing aids, subsections A, C, D, E, F

NB! In Appendix 2.1, the glucoamylase enzyme preparation is described by its commercial name, Attenuzyme Key, or by the internal production batch code PPY75245.

Chapter 3.1, General requirements for applications

A Executive summary

An Executive Summary is provided as a separate copy together with this application.

B Applicant details

(a) **Applicant's name/s**

[REDACTED]

(b) **Company/organisation name**

Novozymes Australia Pty Ltd

(c) **Address (street and postal)**

3/22 Loyalty Road PO Box 4942
2151 NORTH ROCKS NSW, Australia

(d) **Telephone number**

[REDACTED]

(e) **Email address**

[REDACTED]

(f) **Nature of applicant's business**

Biotechnology

(g) **Details of other individuals, companies or organisations associated with the application**

Submission prepared by:

[REDACTED]

C Purpose of the application

This application is submitted to provide for amendment of the Australia New Zealand Food Standards Code, Schedule 18—Processing aids to include a genetically modified strain of *Aspergillus niger* as permitted source for a glucoamylase.

D Justification for the application

The need for the proposed change

Schedule 18—Processing aids contains a list of permitted enzymes of microbial origin, among others glucoamylases (EC 3.2.1.3) from different sources, including *Aspergillus niger*. However, Schedule 18—Processing aids does not contain a glucoamylase (EC 3.2.1.3) from *Aspergillus niger* containing the gene for glucoamylase from *Gloeophyllum sepiarium*.

Aspergillus niger is an approved host and production strain for a number of enzymes in Schedule 18—Processing aids, e.g. a wide range of enzymes that can be used in starch processing such as alpha-amylase, alpha-arabinofuranosidase, cellulase, endo-1,4-beta-xylanase, endo-arabinase, alpha-galactosidase, beta-galactosidase, beta-gluconase, glucoamylase, alpha-glucosidase, beta-glucosidase, hemicellulase multicomponent enzyme.

The advantages of the proposed change over the status quo

The glucoamylase preparation is used as a processing aid during the manufacture of starch-based products. Glucoamylases convert starch by removing D-glucose units in a stepwise manner from the non-reducing end of the substrate molecule to produce glucose for further processing to a wide range of products, such as beer, alcohol, syrups, bread and other cereal based products.

The benefits, which are described above, are not exclusively obtainable by means of enzyme treatment but can be achieved without the use of enzymes, or with a reduced use of enzymes, through e.g. modified maybe more expensive or less environmentally friendly production processes or recipe changes.

D.1 Regulatory impact information

D.1.1 Costs and benefits of the application

The application is not likely to place costs or regulatory restrictions on industry or consumers. Inclusion of the glucoamylase enzyme in Schedule 18—Processing aids will provide the food and beverage industry with the opportunity to improve the yield of fermentable sugars for brewing cereal-based processes, distilled alcohol and baking processing under environmentally friendly and cost efficient production conditions. For the government, the burden is limited to necessary activities for a variation of Schedule 18—Processing aids.

D.1.2 Impact on international trade

The application is not likely to cause impact on international trade.

E Information to support the application

E.1 Data requirements

No public health and safety issues related to the proposed change are foreseen. As outlined in sections 3.3.2 C, D, E, F, the glucoamylase is produced by submerged fermentation of a genetically modified *Aspergillus niger* strain.

The safety of the production organism and the enzyme product has been thoroughly assessed:

- The production organism has a long history of safe use as production strain for food-grade enzyme preparations and is known not to produce any toxic metabolites.
- The genetic modifications in the production organism are well-characterised and safe and the recombinant DNA is stably integrated into the production organism and unlikely to pose a safety concern.
- The enzyme preparation complies with international specifications ensuring absence of contamination by toxic substances or noxious microorganisms
- Sequence homology assessment to known allergens and toxins shows that oral intake of the glucoamylase does not pose food allergenic or toxic concern.
- Two mutagenicity studies *in vitro* showed no evidence of genotoxic potential of the enzyme preparation.
- An oral gavage administration study in rats for 13-weeks showed that all dose levels were generally well tolerated and no evidence of toxicity.

F Assessment procedure

Because the application is for a new source organism for an existing enzyme in the Code, it is considered appropriate that the assessment procedure is characterised as “General Procedure, Level 1”.

G Confidential commercial information (CCI)

Detailed information on the raw materials used in production of the enzyme preparation and construction and characteristics of the genetically modified production strain are provided in **Appendix 4** and **6**, respectively. Summaries of the information are given in section A.4 and 3.3.2 E. The formal request for treatment of selected parts of **Appendix 4** and **6** as confidential commercial information (CCI) is included as **Appendix 1.1**.

H Other confidential information

Apart from the selected parts of **Appendix 4** and **6** identified as confidential commercial information (CCI), no other information is requested to be treated as confidential.

I Exclusive capturable commercial benefit (ECCB)

This application is not expected to confer an Exclusive Capturable Commercial Benefit.

J International and other national standards

J.1 International Standards

Use of enzymes as processing aids for food production is not restricted by any Codex Alimentarius Commission (Codex) Standards.

J.2 Other national standards or regulations

With few exceptions on national, commodity standards, use of enzymes as processing aids for food production is in general not restricted by standards or regulations in other countries.

K Statutory declaration

The Statutory Declaration is provided as a separate document together with this submission.

L Checklist

This application concerns an enzyme product intended to be used as a processing aid. Therefore, the relevant documentation according to the Application Handbook from Food Standards Australia New Zealand as of 1 July 2019, are the following sections:

- Section 3.1.1 – General requirements
- Section 3.3.2 – Processing aids, subsections A, C, D, E, F

Accordingly, the checklist for General requirements as well as the Processing aids part of the checklist for applications for substances added to food was used and is included as **Appendix 1.2 and 1.3**.

Chapter 3.3, Guidelines for applications for substances added to food

3.3.2 Processing Aids

The glucoamylase enzyme preparation described in this application is representative of the commercial food enzyme product for which approval is sought.

A Technical information on the processing aid

A.1 Information on the type of processing aid

The glucoamylase enzyme preparation belongs to the category of processing aids described in Schedule 18—Processing aids.

The glucoamylase enzyme preparation is to be used in the food industry as a processing aid during the processing of raw materials containing starch. Glucoamylase converts starch to D-glucose.

The glucoamylase enzyme preparation is used in the following food manufacturing processes:

- brewing processes
- distilled alcohol processes
- starch processing for glucose syrups production and other starch hydrolysates
- baking processes

The highest dosage of the glucoamylase during a food manufacturing process is brewing processes, where dosages up to 4450 AGU per kg cereals dry matter are used.

A.2 Information on the identity of the processing aid

A.2.1 Enzyme

Generic name	glucoamylase
IUBMC nomenclature	glucan 1,4-alpha-glucosidase
IUBMC No.	EC 3.2.1.3
Cas No.	9032-08-0

A.2.2 Enzyme preparation

The enzyme concentrate is formulated into a final enzyme preparation. The enzyme concentrate may be intended for a single enzyme preparation or a blend with other food enzymes and formulated as a liquid product depending on the characteristics of the intended food process in which it will be used.

The typical composition of the enzyme concentrate is:

Enzyme solids (TOS) ¹	approx. 31 %
Sucrose/Glucose	approx. 6.5 %
Sodium benzoate	approx. 0.35 %
Potassium sorbate	approx. 0.15 %
Water	approx. 62 %

The enzyme concentrate is standardised in glucoamylase units to an activity of 1680 AGU/g. The Novozymes method used to determine the AGU activity is enclosed in **Appendix 3.2**.

A.2.3 Host organism

The production strain was developed from the *Aspergillus niger* BO-1 cell lineage, which was derived from the natural isolate *Aspergillus niger* C40-1. The C40-1 cell lineage has a long history of safe use at Novozymes for production of food enzymes and has given rise to a number of food enzyme production strains, which are used for production of previously evaluated and regulatory approved food enzymes. The taxonomic classification of the strain is:

Division	Ascomycota
Class	Eurotiomycetes
Order	Eurotiales
Family	Trichocomaceae
Genus	<i>Aspergillus</i>
Species	<i>Aspergillus niger</i>

For a more detailed description of the host organism and the genetic modifications, please see section 3.3.2 E.

A.2.4 Donor organism

The donor for the glucoamylase gene is *Gloeophyllum sepiarium*.

Division	Basidiomycota
Class	Agaricomycetes
Order	Gloeophyllales
Family	Gloeophyllaceae
Genus	<i>Gloeophyllum</i>
Species	<i>sepiarium</i>

¹ TOS = Total Organic Solids, defined as: 100 % - water - ash - diluents

The glucoamylase enzyme protein has been protein-engineered. For a more detailed description of the donor and the donor gene, please see section 3.3.2 E and **Appendix 6**.

A.3 Information on the chemical and physical properties of the processing aid

The enzyme is a glucan 1,4- α -glucosidase (EC 3.2.1.3), commonly known as glucoamylase. Glucan 1,4- α -glucosidase catalyses the hydrolysis of (1 \rightarrow 4)- α - as well as (1 \rightarrow 6)- α -linkages in the starch polysaccharides amylose and amylopectin.

The enzyme preparation is available as liquid/granulate product. The appearance of the enzyme product is given in **Appendix 2.1**. The micro-organisms used for fermentation will consume the majority of the raw materials. Subsequent down-stream processes, such as washing and filtration steps will remove remaining amounts of raw material. Thus, the final food enzyme product will not contain significant residual amounts of the nutrients used for fermentation. This is confirmed by regular spot-testing, where analytical measurements show no detectable amounts of the allergens listed in **Appendix 2.1**.

The glucan 1,4- α -glucosidase is active at temperatures up to approximately 95 °C (with an optimum 65-70 °C at pH 5), and within a pH range of 2 to 6 (with an optimum of pH 3-5 at 37 °C). The temperature stability of the glucan 1,4- α -glucosidase was determined at pH 5 and 30 minutes incubation showing that the enzyme retained almost full activity up to 60 °C, and that no activity remained at 75 °C and above. The food processes, in which the enzyme is applied, include processing steps where it is denatured at high temperatures.

The food enzyme object of the present application is not added to final foodstuffs but used as a processing aid during food manufacturing. The enzyme exerts no function in the final food. In the final food the enzyme protein is either denatured by high temperature, which means that it does not have any action or any function, and is thus, like any other protein, inert; and/or removed in certain processing steps.

No reaction products, which could not be considered normal constituents of the diet, are formed during the production or storage of the enzyme-treated food.

A.4 Manufacturing process

The manufacturing process comprises a fermentation process, a purification process, a formulation process and finally a quality control of the finished product, as outlined by Aunstrup (1979). This section describes the processes used in manufacturing of the glucoamylase enzyme product.

The enzyme preparation is manufactured in accordance with current Good Manufacturing Practices (**Appendix 4.1**). The quality management system used in the manufacturing process complies with ISO 9001:2015 (**Appendix 4.2**).

The raw materials are of food-grade quality and have been subjected to appropriate analysis to ensure their conformity with the specifications.

A.4.1 Fermentation

The glucoamylase is produced by submerged fed-batch pure culture fermentation of the genetically modified strain of *Aspergillus niger*, described in section 3.3.2 E.

A.4.1.1 Raw materials for fermentation

The production strain is grown in a medium consisting of compounds providing an adequate supply of carbon and nitrogen as well as minerals and vitamins necessary for growth. Furthermore, acids and bases for the adjustment of the pH and processing aids (e.g. antifoaming agents) are used during fermentation. The choice of raw materials used in the fermentation process (the feed, the seed fermenter, the main fermenter and dosing) is given in the confidential parts of **Appendix 4.3**.

A.4.1.2 Hygienic precautions

All equipment is designed and constructed to prevent contamination by foreign microorganisms.

All valves and connections not in use for the fermentation are sealed by steam at more than 120 °C.

After sterilization a positive pressure of more than 0.2 atmosphere is maintained in the fermentation tank.

The air used for aeration is sterilised by passing through a sterile filter. The inside of each fermentation tank is cleaned between fermentations by means of a high-pressure water jet and inspected after the cleaning procedures have been completed.

A.4.1.3 Preparation of the inoculum

The inoculum flask containing the prepared medium is autoclaved and checked. Only approved flasks are used for inoculation.

The stock culture suspension is injected aseptically into the inoculum flask and spread onto the medium in the flask. Once growth has taken place in the inoculum flask (typically after a few days at 30°C), the following operations are performed:

- Strain identity and traceability: ampoule number is registered
- Microbial purity: a sample from the inoculum flask is controlled microscopically for absence of microbial contaminants.

When sufficient amount of biomass is obtained and when the microbiological analyses are approved, the inoculum flask can be used for inoculating the seed fermenter.

A.4.1.4 The seed fermentation

The raw materials for the fermentation medium are mixed with water in a mixing tank. The medium is transferred to the seed fermenter and heat sterilised (e.g. 120 °C/60 min).

The seed fermentation tank is inoculated by transferring aseptically a suspension of cells from the inoculum flask.

The seed fermentation is run aerobically (sterile airflow), under agitation. The overpressure is kept above 0.2 atmosphere at all times, to prevent contamination.

Once a sufficient amount of biomass has developed, microbiological analyses are performed to ensure absence of contamination. The seed fermentation can then be transferred to the main fermentation tank.

A.4.1.5 The main fermentation

The raw materials for the medium are mixed with water in a mixing tank. The medium is transferred to the main fermenter and heat sterilised (e.g. 120 °C/60 min). If necessary, the pH is adjusted after sterilization, with sterile pH adjustment solutions.

The fermentation in the main tank is run as normal submerged fed-batch fermentation.

The main fermentation is run aerobically (sterile airflow), under vigorous agitation. The overpressure is kept above 0.2 atmosphere at all times, to prevent contamination. The fermentation is run at a well-defined temperature.

Fresh medium is added aseptically when the pH increases above its set point, and the dissolved oxygen concentration rises. The feed rate is adjusted so that there is no accumulation of carbohydrates.

Other parameters are measured at regular intervals

- refractive index
- enzyme productivity
- residual glucose
- residual ammonia

Samples are also taken at regular intervals to check absence of microbial contamination.

A.4.2 Recovery

The recovery process is a multi-step operation designed to separate the enzyme from the microbial biomass and partially purify, concentrate, and stabilize the food enzyme.

The steps of this process involve a series of typical unit operations:

- pre-treatment
- primary separation
- filtration
- concentration
- evaporation
- preservation and stabilization

A.4.2.1 Raw materials for recovery

The choice of raw materials used during recovery is given in the confidential parts of **Appendix 4.3**.

A.4.2.2 Pre-treatment

To facilitate the separation, flocculants are used in a pH-controlled process.

A.4.2.3 Primary separation

The cell mass and other solids are separated from the broth by well-established techniques such as pre-coat vacuum drum filtration or centrifugation.

The primary separation is performed at well-defined pH and temperature range.

A.4.2.4 Filtration

For removal of residual cells of the production strain and as a general precaution against microbial degradation, filtration on dedicated germ filtration media is applied. Pre-filtration is included when needed.

The filtrations are performed at well-defined pH and temperature intervals, and result in an enzyme concentrate solution free of the production strain and insoluble substrate components from the fermentation.

A.4.2.5 Concentration

Ultrafiltration and/or evaporation are applied for concentration and further purification. The ultrafiltration is applied to fractionate high molecular weight components (enzymes) from low molecular weight components and is used to increase the activity/dry matter ratio. Evaporation is used to increase the activity while maintaining the activity/dry matter ratio.

The pH and temperature are controlled during the concentration step, which is performed until the desired activity and activity/dry matter ratio has been obtained.

A.4.2.6 Evaporation

Evaporation is performed to remove water and increase the refractive index. The concentration is run at 0-45 °C and the refractive index is controlled during the concentration step to ensure that the dry matter content is within a given range.

A.4.2.7 Preservation and stabilization

For enzymatic, physical and microbial stabilization, sucrose/glucose is added to the enzyme concentrate.

A.4.2.8 Process control

Apart from the process controls performed during the various fermentation steps and described above, the following microbial controls are also performed.

Samples are withdrawn from both the seed fermenter and the main fermenter:

- before inoculation
- at regular interval during cultivation
- before transfer/harvest

The samples during all steps are examined by:

- microscopy
- plating culture broth on a nutrient agar and incubating for 24-48 hours

Growth characteristics are observed macroscopically and microscopically.

During the microbiological control steps, the number of foreign microorganisms should be insignificant. The fermentation parameters, *i.e.* enzyme activity, temperature and oxygen as well as pH are also monitored closely. A deviation from the normal course of the fermentation may signal a contamination.

If a significant contamination develops, the fermentation is terminated. The fermentation is regarded as “significantly contaminated” if two independent samples show presence of contaminating organisms after growth on nutrient agar.

Any contaminated fermentation is rejected for enzyme preparations to be used in a food-grade application.

A.5 Specification for identity and purity

The glucoamylase enzyme product complies with the purity criteria recommended for Enzyme Preparations in Food, Food Chemicals Codex, 11th edition, 2018.

In addition to this, the glucoamylase enzyme product also conforms to the General Specifications for Enzyme Preparations Used in Food Processing as proposed by the Joint FAO/WHO Expert Committee on Food Additives in Compendium of Food Additive Specifications.

Analytical data for three representative, unstandardised batches of the glucoamylase enzyme preparation are shown in (Table 1). These data show compliance with the purity criteria of the specification.

Table 1. Analytical data for three representative enzyme product batches

Control parameter	Unit	Specification	Batch 1	Batch 2	Batch 3
glucoamylase activity	AGU/g		668	718	817
Lead	mg/kg	≤ 2	ND (LOD < 0.5)	ND (LOD < 0.5)	ND (LOD < 0.5)
Arsenic	mg/kg	≤ 1	ND (LOD < 0.3)	ND (LOD < 0.3)	ND (LOD < 0.3)
Cadmium	mg/kg	≤ 1	ND (LOD < 0.05)	ND (LOD < 0.05)	ND (LOD < 0.05)
Mercury	mg/kg	≤ 1	ND (LOD < 0.05)	ND (LOD < 0.05)	ND (LOD < 0.05)
Total viable count	CFU/g		<100	<100	<100
Total coliforms	CFU/g	≤ 30	<4	<4	<4

Control parameter	Unit	Specification	Batch 1	Batch 2	Batch 3
Enteropathogenic <i>Escherichia coli</i>	CFU/25 g	ND	ND	ND	ND
<i>Salmonella</i> spp.	CFU/25 g	ND	ND	ND	ND
Antimicrobial activity	—	ND	ND	ND	ND
Ochratoxin A	mg/kg		ND (LOD < 0.0003)	ND (LOD < 0.0003)	ND (LOD < 0.0003)
Fumonisin B2	mg/kg		ND (LOD < 0.0003)	ND (LOD < 0.0003)	ND (LOD < 0.0003)
Production strain	CFU/g	ND	ND	ND	ND

ND: not detected; LOD: limit of detection ; CFU: colony forming unit

A certificate of analysis of the presented data is attached as **Appendix 3.1**. The methods of analysis used to determine compliance with the specifications are enclosed (**Appendix 3**).

The glucoamylase enzyme preparation is available as a liquid/granulate enzyme product. The concentrate is standardised in glucoamylase units (AGU/g; **Appendix 3.2**). The preparation does not contain known food allergens (**Appendix 2.1** and **Appendix 4.3**).

A.6 Analytical method for detection

The glucoamylase enzyme preparation is to be used in the food industry as a processing aid. This information is not required in the case of an enzymatic processing aid.

B Information related to the safety of a chemical processing aid

Not applicable – this application does not concern a chemical processing aid.

C Information related to the safety of an enzyme processing aid

C.1 General information on the use of the enzyme as a food processing aid in other countries

The enzyme is used as processing aid during processing of starch-containing raw materials in a range of countries, where there are no restrictions of the use of enzyme processing aids or where the enzyme is covered by a country positive list or specific approval.

The safety of the glucoamylase preparation has been evaluated and confirmed by external expert groups, as follows:

- Denmark: The enzyme preparation was safety assessed resulting in the authorisation of the enzyme product by the Danish Veterinary and Food Administration.

C.2 Information on the potential toxicity of the enzyme processing aid

(a) Information on the enzyme's prior history of human consumption and/or its similarity to proteins with a history of safe human consumption

A wide variety of enzymes are used in food processing. Enzymes, including glucoamylase, have a long history of use in food (Pariza and Foster, 1983; Pariza and Johnson, 2001).

Since the 1960s glucoamylases have been used extensively in various industrial food applications for the hydrolysis of starch to fermentable sugars, with major application in the starch, distilling, brewing, and baking industry (Godfrey, 1983; Janda, 1983; Poulson, 1983; Reichelt, 1983; van Oort, 2010). Glucoamylase enzyme preparations from various sources are widely authorised in, e.g. Australia and New Zealand, Brazil, Canada, China, Denmark, France, Japan, Mexico.

(b) Information on any significant similarity between the amino acid sequence of the enzyme and that of known protein toxins

A sequence homology assessment of the glucoamylase enzyme to known toxins was conducted. The amino acid sequence of the glucoamylase provided in **Appendix 6.4** was used as input for the search. No homologies to known toxins were found. The complete search report is enclosed in **Appendix 5.1**.

Furthermore, safety studies as described below were performed on a representative batch (PPY75245) that was produced according to the description given in section 3.3.2 A.4, omitting stabilization and standardization. As a result, batch (PPY75245 represents the enzyme concentrate and not the final enzyme product.

A summary of the safety studies is enclosed in **Appendix 5.2**.

The following studies were performed:

- Ames Test. Test for mutagenic activity (**Appendix 5.3**)
- *In vitro* micronucleus test (**Appendix 5.4**)
- Toxicity study by oral gavage administration to rats for 13 weeks (**Appendix 5.5**)

The main conclusions of the safety studies can be summarised as follows:

- Glucoamylase PPY75245 did not induce gene mutations in bacteria either in the presence or absence of metabolic activation (S-9) when tested under the conditions employed in this study.
- Glucoamylase PPY75245 did not show evidence of causing an increase in the induction of micronuclei in cultured human lymphocytes, in this *in vitro* test system under the experimental conditions.
- Oral gavage administration of Glucoamylase PPY75245 to rats at doses up to 100 % of the tox test batch (equivalent to 1070.2 mg TOS/kg bw/day) for 13 weeks was well-tolerated and did not cause any adverse change. The NOAEL was considered to be 100 % of the tox test batch (equivalent to 1070.2 mg TOS/kg bw/day).

Based on the presented toxicity data it can be concluded that the glucoamylase enzyme preparation, represented by batch PPY75245, exhibits no toxicological effects under the experimental conditions described.

C.3 Information on the potential allergenicity of the enzyme processing aid

(a) Information of the source of the enzyme processing aid

The glucoamylase enzyme is produced by an *Aspergillus niger* microorganism expressing the glucoamylase from *Gloeophyllum sepiarium*. *Aspergillus niger* is ubiquitous in the environment and in general considered as a non-pathogenic fungus (see Section 3.3.2 D).

(b) Analysis of similarity between the amino acid sequence of the enzyme and that of known allergens

Enzymes have a long history of safe use in food, with no indication of adverse effects or reactions. Moreover a wide variety of enzyme classes (and structures) are naturally present in food.

The allergenicity potential of enzymes was studied by Bindslev-Jensen et al. (2006) and reported in the publication: "Investigation on possible allergenicity of 19 different commercial enzymes used in the food industry". The investigation comprised enzymes produced by wild-type and genetically modified strains as well as wild-type enzymes and protein engineered variants and comprised 400 patients with a diagnosed allergy to inhalation allergens, food allergens, bee or wasp. It was concluded from this study that ingestion of food enzymes in general is not likely to be a concern with regard to food allergy.

Additionally, food enzymes are used in small amounts during food processing resulting in very small amounts of the enzyme protein in the final food. A high concentration generally equals a higher risk of sensitization, whereas a low level in the final food equals a lower risk (Goodman et al., 2008).

A sequence homology assessment of the glucoamylase enzyme to known allergens was conducted (**Appendix 5.1**). The amino acid sequence of the glucoamylase provided in **Appendix 6.4** was used as input for the search. The glucoamylase was compared to allergens from the FARRP allergen protein database (<http://www.allergenonline.org>).

The analyses of the glucoamylase's sequence identified homology to Sch c 1, a known allergen, above the threshold of 35 % across an 80 amino acid window (Appendix 5.1). The sequence homology assessment identified 81.25 % and 81.01 % (without and with scaling) to Sch c 1, a glucoamylase originating from *Schizophyllum commune*. Sch c 1 is not known to be a food allergen. However, it is known as a respiratory, occupational allergen.

There is compelling evidence that the vast majority of adults affected by occupational asthma can ingest the respiratory allergen without acquiring clinical symptoms of food allergy, suggesting that inhalation is not likely to result in food allergy (Brisman, 2002; Poulsen, 2004; Armentia et al, 2009).

This is backed up by a study using the generally recognised guidelines for food allergy diagnosis (Bindslev-Jensen et al, 2006 as also described above). The study included 400 patients with diagnosed allergy to one or more of: inhalation allergens, food allergens, bee or wasp allergens. It should be noted that one of the tested enzymes was a glucoamylase that had a sequence identity to Sch c 1 of up to 68 % and a sequence identity to another occupational allergen (*Aspergillus niger* alpha-amylase Asp o 21) of up to 81 %. None of the tested patients showed an allergic reaction against the tested glucoamylase when applied orally. There were no indications of cross-reactivity between the tested enzymes used in food and the main known allergens represented by the patients included in the study.

On the basis of the available evidence it is concluded that oral intake of the glucoamylase is not anticipated to pose any food allergenic concern.

C.4 Safety assessment reports prepared by international agencies or other national government agencies, if available

Documentation of approval of the glucoamylase in Denmark is enclosed in **Appendix 2**.

D Additional information related to the safety of an enzyme processing aid derived from a microorganism

D.1 Information on the source microorganism

The glucoamylase enzyme is produced by an *Aspergillus niger* microorganism expressing the glucoamylase from *Gloeophyllum sepiarium*. The host strain is a modified (protease-deficient) *Aspergillus niger* strain (BO-1) derived from a natural isolate of *Aspergillus niger* C40-1. The C40-1 cell lineage has a long history of safe use at Novozymes for production of food enzymes and has given rise to a number of food enzyme production strains, which are used for production of previously evaluated and regulatory approved food enzymes.

The glucoamylase production strain is a non-pathogenic, non-toxicogenic, genetically modified *Aspergillus niger* strain. The production strain is marker-free, and it does not produce secondary metabolites of toxicological concern to humans as explained in Section E 1.3, Section A.5 and **Appendix 6.1**.

D.2 Information on the pathogenicity and toxicity of the source microorganism

Aspergillus niger is ubiquitous in the environment and in general considered as a non-pathogenic fungus.

Aspergillus niger is classified as a group 1 microorganism according to EU Directive 2000/54/EC of the European Parliament and of the Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work. A group 1 microorganism means one that is unlikely to cause human disease.

Aspergillus niger as a species has been used safely for the production of food ingredients (e.g. citric acid) and food enzymes world-wide for decades.

Schuster et al. (2002) reviewed the safety of *Aspergillus niger* and describe it as having a very long history of safe industrial use, being widely distributed in nature, and being commonly used for production of food enzymes and citric acid.

Aspergillus niger has been used in the industry since 1919, for instance for the production of citric acid, which could be an ingredient of foods such as soft drinks, fruit juices and jams. The US Food and Drug Administration (FDA) has listed *Aspergillus niger* as a source of citric acid (21 CFR §173.280).

The JECFA (Joint FAO/WHO Expert Committee on Food Additives) has evaluated enzyme preparations derived from *Aspergillus niger*. This body of experts determined that enzymes from this source do not constitute a toxicological hazard (JECFA, 1990).

Carbohydrase, pectinase, protease, glucose oxidase, catalase, lipase and lactase enzyme preparations from *Aspergillus niger* are included in the GRAS petition 3G0016 (filed April 12th, 1973) that FDA on request from the Enzyme Technical Association (ETA) converted into separate GRAS Notices (GRN 89, 111, 132). Based on the information provided by ETA, as well as the information in GRP 3G0016 and other information available to FDA, the agency did not question the conclusion that enzyme preparations from *Aspergillus niger* are GRAS under the intended conditions of use. Analogous conclusions were drawn in GRAS Notices GRN 158, 183, 214, 296, 345, 402, 428, 510, 651, 657, 699, 703, and 739 which all describe food enzymes produced by *Aspergillus niger* strains.

Overall, it can be concluded that *Aspergillus niger* is widely accepted as a non-pathogenic organism and that it has a long history of safe use in food and food enzyme production.

D.3 Information on the genetic stability of the source organism

The inserted recombinant DNA is genetically stable during fermentation, as the inserted DNA is integrated into the chromosome.

Stability of the introduced DNA sequences was analysed using phenotypic characteristics of the production strain, *i.e.* enzyme activity and protein synthesis (**Appendix 6.5**).

For a more detailed description of the strain construction and characteristics, please see section 3.3.2 E.

E Additional information related to the safety of an enzyme processing aid derived from a genetically-modified microorganism

E.1 Information on the methods used in the genetic modification of the source organism

This section contains summarised information on the modifications of the host strain, on the content and nature of the introduced DNA and on the construction of the final production strain, as well as the stability of the inserted gene. The detailed information is provided in the confidential **Appendix 6**.

E.1.1 Host organism

The production strain was developed from the *Aspergillus niger* BO-1 cell lineage, which was derived from the natural isolate *Aspergillus niger* C40-1. The C40-1 cell lineage has a long history of safe use at Novozymes for production of food enzymes and has given rise to a number of food enzyme production strains, which are used for production of previously evaluated and regulatory approved food enzymes. The taxonomic classification of the strain is:

Division	Ascomycota
Class	Eurotiomycetes
Order	Eurotiales
Family	Trichocomaceae
Genus	<i>Aspergillus</i>
Species	<i>Aspergillus niger</i>

The recipient strain used in the construction of the *Aspergillus niger* production strain, was derived from the parental strain through a combination of classical mutagenesis/selection and GM-steps. These steps were carried out in order to simplify purification, enhance product stability and increase the safety of the strain.

E.1.2 Introduced DNA

The vector used to transform the *Aspergillus niger* recipient strain are based on an *Escherichia coli* standard vector (Vieira and Messing, 1989). No elements of the vector are left in the production strain. Both vectors contain a glucoamylase expression cassette consisting of a hybrid *Aspergillus* promoter, the coding sequence for glucoamylase from *Gloeophyllum sepiarium* and an *Aspergillus niger* terminator. The glucoamylase gene is a product from a PCR reaction from genomic DNA isolated from *Gloeophyllum sepiarium*. Furthermore, the vectors contain expression cassettes to introduce two marker genes for selection of successful transformants during the construction of the production strain.

E.1.3 Construction of the recombinant microorganism

The *Aspergillus niger* production strain was constructed from the recipient strain through the following steps:

1. The glucoamylase expression cassette was integrated at specific integration sites present in the recipient strain.
2. A transformant was screened for rapid growth and high glucoamylase activity leading to the final production strain.

E.1.4 Antibiotic resistance gene

No functional antibiotic resistance genes were left in the strain as a result of the genetic modifications. Further details can be found in **Appendix 6.1**

E.1.5 Stability of the introduced genetic sequences

The transforming DNA is stably integrated into the *Aspergillus niger* chromosome and, as such, is poorly mobilised for genetic transfer to other organisms and is mitotically stable. Stability of the introduced DNA sequence was analysed using phenotypic characteristics of the production strain, *i.e.* enzyme activity and protein synthesis. Further details can be found in **Appendix 6.4**.

F Information related to the dietary exposure to the processing aid

F.1 A list of foods or food groups likely to contain the processing aid or its metabolites

The glucoamylase preparation is used as a processing aid during the manufacture of starch-based products. Glucoamylases convert starch by removing D-glucose units in a stepwise manner from the non-reducing end of the substrate molecule to produce glucose for further processing to a wide range of products, such as beer, alcohol, syrup, bread, and other cereal-based products.

F.2 The levels of residues of the processing aid or its metabolites for each food or food group

The glucoamylase enzyme preparation is used in the following food manufacturing processes:

Use level

The enzyme preparation is used at minimum levels necessary to achieve the desired effect and according to requirements for normal production following GMP.

The conditions of use of the glucoamylase preparation during food processing do not only depend on the type of application, but also on the food production process of each individual food manufacturer. In order to ensure optimal effectiveness of the enzyme at an acceptable economic cost the dosage, reaction time, process conditions and processing steps are adjusted.

The highest dosage given for solid food is 3200 AGU per kg flour dry matter. This corresponds to 1.90 g of glucoamylase enzyme preparation per kg flour equivalent to 590 mg TOS per kg flour.

The highest dosage given for liquids is 4450 AGU per kg starch dry matter. This corresponds to 2.65 g of glucoamylase enzyme preparation per kg starch (or starch-derived) dry matter equivalent to 821 mg TOS per kg starch (or starch-derived) dry matter.

Enzyme residues in the final food

The glucoamylase enzyme preparation is used in processing of raw materials containing starch for the hydrolysis of starch to glucose. The enzyme is denatured by heat during processing or removed by down-stream processes.

F.2.1 Estimates of human consumption

Method used for the dietary exposure assessment

An exposure assessment according to the Budget Method (Douglass et al., 1997; Hansen, 1966; ILSI, 1997) has been performed, as the processed starch is used as an ingredient in a variety of food products and beverages.

Budget Method

Overall, the human exposure to the glucoamylase will be negligible because the enzyme preparation is used as a processing aid and in low dosages.

The Budget Method assumptions represent a “maximum worst case” situation of human consumption, in which the food enzyme object of the present application would be used at its maximum recommended dosages in all processed food and all processed beverages and not only in those food and drink processes described in Section F.2.

It is also supposed that the totality of the food enzyme will end up in the final food. This assumption is exaggerated since the enzyme protein and the other substances resulting from the fermentation are diluted or removed in certain processing steps.

As an example distilled beverage spirits will neither contain any TOS (Total Organic Solids) originating from the food enzyme preparation nor from the fermentation mash due to the distillation step(s).

Therefore the safety margin calculation derived from this method is highly conservative.

Assumptions in the Budget Method

Solids	The maximum energy intake over the course of a lifetime is 50 kcal/kg body weight/day.
	50 kcal corresponds to 25 g foods.
	Therefore, adults ingest 25 g foods per kg body weight per day.
	Assuming that 50 % of the food is processed food, the daily consumption will be 12.5 g processed foods per kg body weight.
	It is further assumed that, in average, all processed food contains 25 % ² starch (or starch-derived) dry matter = 3.12 g starch (or starch-derived) dry matter per kg body weight per day.
Liquids	The maximum intake of liquids (other than milk) is 100 ml/kg body weight/day.
	Assuming that 25 % of the non-milk beverages is processed, the daily consumption will be 25 ml processed beverages per kg body weight.

² For starch (or starch-derived) dry matter, this assumption was explained in an answer to application A1248.

	It is further assumed that all processed beverages contain 12 % ³ starch (or starch-derived) dry matter = 3.0 g starch (or starch-derived) dry matter per kg body weight per day.
	It is assumed that the densities of the beverages are ~ 1.

TMDI (Total amount of dietary intake) calculation

Solid food

The highest dosage given for solid food is 3200 AGU per kg flour dry matter, corresponding to 590 mg TOS per kg flour dry matter (cf. Section 3.3.2 A.2.2).

Based on this, 3.12 g starch (or starch-derived) dry matter in solid food will maximally contain:
 590 mg TOS per kg / 1000 g per kg x 3.12 g = 1.84 mg TOS

Liquids

The highest dosage given for liquids is 4450 AGU per kg starch (or starch-derived) dry matter, corresponding to 821 mg TOS per kg starch (or starch-derived) dry matter (cf. Section 3.3.2 A.2.2).

Based on this, 3.0 g starch (or starch-derived) dry matter in liquids will maximally contain:
 821 mg TOS per kg / 1000 g per kg x 3.0 g = 2.46 mg TOS

Total TMDI of starch (or starch-derived) solid foods and liquids

1.84 mg TOS + 2.46 mg TOS = 4.30 mg TOS

F.2.2. Safety Margin Calculation

The safety margin is calculated as dose level with no adverse effect (NOAEL) divided by the estimated human consumption (TMDI). The NOAEL dose level in the 13 weeks oral toxicity study in rats was concluded to be 1070.2 mg TOS/kg bw/day (cf. Section 3.3.2 C 2).

The estimated human consumption is 4.30 mg TOS/kg/day

The safety margin can thus be calculated to be $1070.2/4.30 \approx 249$.

F.3 For foods or food groups not currently listed in the most recent Australian or New Zealand National Nutrition Surveys (NNSs), information on the likely level of consumption

Not relevant.

³ For starch (or starch-derived) dry matter, this assumption was explained in an answer to application A1248.

F.4 The percentage of the food group in which the processing aid is likely to be found or the percentage of the market likely to use the processing aid

It is assumed that all raw materials containing starch are processed using the glucoamylase object of this submission as a processing aid at the highest recommended dosage.

F.5 Information relating to the levels of residues in foods in other countries

As described in F.2.1 above, a “worst case” calculation is made assuming that all organic matter originating from the enzyme is retained in the processed food product. The dietary exposure is estimated using the Budget Method, as the processed starch are used as an ingredient in a variety of food products.

F.6 For foods where consumption has changed in recent years, information on likely current food consumption

No significant changes in recent years are observed.

List of references

- Armentia A, Días-Perales A, Castrodeza J, Dueñas-Laita A, Palacin A, Fernández S (2009) Why can patients with baker's asthma tolerate wheat flour ingestion? Is wheat pollen allergy relevant? *Allergol. Immunopathol.* 37 (4), 203-204.
- Aunstrup K (1979) Production, isolation, and economics of extracellular enzymes. In: *Applied Biochemistry and Bioengineering*. Elsevier, pp. 27–69.
- Bindslev-Jensen C, Skov PS, Roggen EL, Hvass P and Brinch DS (2006) Investigation on possible allergenicity of 19 different commercial enzymes used in the food industry. *Food and Chemical Toxicology* 44(11). Elsevier: 1909–1915.
- Brisman J (2002) Baker's Asthma. *Occup. Environ. Med.* 59, 498-502.
- Douglass JS, Barraji LM, Tennant DR, Long WR and Chaisson CF (1997) Evaluation of the budget method for screening food additive intakes. *Food Additives & Contaminants* 14(8). Taylor & Francis: 791–802.
- Godfrey T (1983) Brewing. *Industrial Enzymology. The application of enzymes in industry* (Godfrey T, Reichelt J eds.) The Nature Press, New York, 221-259.
- Goodman RE, Vieths S, Sampson HA, Hill D, Ebisawa M, Taylor SL and Van Ree R (2008) Allergenicity assessment of genetically modified crops—what makes sense? *Nature biotechnology* 26(1). Nature Publishing Group: 73–81.
- Hansen SC (1966) Acceptable daily intake of food additives and ceiling on levels of use. *Food and cosmetics toxicology* 4. Elsevier: 427–432.
- ILSI (1997) An evaluation of the budget method for screening food additive intake. Summary report of an ILSI Europe food chemical intake task force. ILSI Europe, Brussels, Belgium.
- Janda W (1983) Fruit Juice. *Industrial Enzymology. The application of enzymes in industry* (Godfrey T, Reichelt J eds.) The Nature Press, New York, 315-320.
- JECFA (1990) Enzyme preparations. In: *Evaluation of certain food additives and contaminants : Thirty-fifth report of the joint FAO/WHO expert committee on food additives [meeting held in rome from 29 may to 7 june 1989]*, Geneva, 1990. World Health Organization. Available at: <https://apps.who.int/iris/handle/10665/37651>.
- Pariza MW and Foster EM (1983) Determining the safety of enzymes used in food processing. *Journal of Food Protection* 46(5). International Association for Food Protection: 453–468.
- Pariza MW and Johnson EA (2001) Evaluating the safety of microbial enzyme preparations used in food processing: Update for a new century. *Regulatory Toxicology and Pharmacology* 33(2). Elsevier: 173–186.
- Poulsen LK (2004) Allergy assessment of foods or ingredients derived from biotechnology, gene-modified organisms, or novel food. *Mol. Nutr. Food Res.* 48, 413-423.
- Poulson PB (1983) Alcohol - Potable. *Industrial Enzymology. The application of enzymes in industry* (Godfrey T, Reichelt J eds.) The Nature Press, New York, 170-178.

Reichelt JR (1983) Starch. *Industrial Enzymology. The application of enzymes in industry* (Godfrey T, Reichelt J eds.) The Nature Press, New York, 375-396.

Schuster E, Dunn-Coleman N, Frisvad JC and Van Dijck PW (2002) On the safety of *Aspergillus niger*—a review. *Applied microbiology and biotechnology* 59(4). Springer: 426–435.

van Oort M (2010) Enzymes in bread making. *Enzymes in Food Technology* (RJ Whitehurst, M van Oort M, eds) Wiley-Blackwell, UK. 103-143.

Vieira J and Messing J (1989) Production of single-stranded plasmid DNA. *Recombinant DNA Methodology*. Elsevier: 225–233.

List of appendices

Appendices listed in **red, bold** font should be treated as confidential commercial information.

Appendix 1.1 Formal request for treatment of confidential commercial information (CCI)

Appendix 1.2 Checklist for general requirements

Appendix 1.3 Checklist for applications for substances added to food

Appendix 2.1 Product data sheet

Appendix 2.2 Danish approval document

Appendix 3.1 Certificate of analysis

Appendix 3.2 Method to determine Glucoamylase activity

Appendix 3.3 Method to determine heavy metals

Appendix 3.4 Method to determine total viable count

Appendix 3.5 Method to determine total coliforms

Appendix 3.6 Method to determine *Escherichia coli*

Appendix 3.7 Method to determine *Salmonella* spp.

Appendix 3.8 Method to determine antimicrobial activity

Appendix 3.9 Method to determine mycotoxins

Appendix 4.1 GMP statement

Appendix 4.2 ISO certificate

Appendix 4.3 CCI [REDACTED]

Appendix 4.3 non-CCI Raw Materials used during fermentation and recovery

Appendix 5.1 Sequence homology assessment

Appendix 5.2 Summary of toxicity data

Appendix 5.3 Ames test report

Appendix 5.4 *In vitro* micronucleus study

Appendix 5.5 Toxicity study by oral gavage administration to rats for 13 weeks

Appendix 6 CCI [REDACTED]

Appendix 6 non-CCI Documentation regarding the production strain